Mr. Ibrahem/Belimumab
Fab fragment of belimumab. PDB: 5Y9K​.
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetB-cell activating factor (BAFF, BLyS)
Clinical data
Trade namesBenlysta
Other namesLymphoStat-B
AHFS/Drugs.comMonograph
MedlinePlusa611027
License data
Pregnancy
category
Routes of
administration
Intravenous
Legal status
Legal status
Chemical and physical data
FormulaC6714H10428O2102S52
Molar mass126450.30 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Belimumab, sold under the brand name Benlysta, is a medication used to treat systemic lupus erythematosus (SLE) or lupus nephritis.[2] It is used in addition to other treatments, when those are not sufficient.[4] It is given by injection into a vein or under the skin.[2]

Common side effects include respiratory tract infections, diarrhea, and shingles.[3] Other side effects may include infusion reactions, progressive multifocal leukoencephalopathy, depression, and anaphylaxis.[3][2] It is a monoclonal antibody that attaches too and blocks B-cell activating factor (BAFF), shortening the lifespan of B lymphocytes.[3]

Belimumab was approved for medical use in the United States and Europe in 2011.[3][2] In the United Kingdom 400 mg costs the NHS about £405 as of 2021.[4] This amount in the United States costs about 1,950 USD.[5]

References edit

  1. ^ a b "Belimumab (Benlysta) Use During Pregnancy". Drugs.com. 5 February 2020. Archived from the original on 4 December 2020. Retrieved 29 July 2020.
  2. ^ a b c d e f "Benlysta- belimumab injection, powder, lyophilized, for solution Benlysta- belimumab solution". DailyMed. 17 January 2020. Archived from the original on 25 September 2020. Retrieved 29 July 2020.
  3. ^ a b c d e f "Benlysta EPAR". European Medicines Agency (EMA). Archived from the original on 25 October 2020. Retrieved 29 July 2020.
  4. ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 891. ISBN 978-0857114105.
  5. ^ "Benlysta Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 8 January 2022.